closedosingdownloadefficacymoasafetytable-checktable-cross

The OTEZLA® international website

This site is intended for healthcare professionals outside the U.S.

OTEZLA IMPROVES SKIN PLAQUES1*

Efficacy in moderate patients is consistent with the overall ESTEEM population

Improvement in PASI-75 response at week 16 in the ESTEEM moderate patient subset1,a,b

aPooled ESTEEM 1 and ESTEEM 2 studies. Post-hoc analysis of OTEZLA vs placebo at week 16 in moderate patients (baseline sPGA score of 3, BSA of 10% to 15%, PASI score of 12 to 15). A total of 224 patients met these criteria at baseline (OTEZLA, n = 160; placebo, n = 64).

bIncludes all patients in each indicated group with moderate to severe scalp psoriasis (ScPGA ≥3) at baseline; patients with a missing value at week 16 were considered non-responders.

OTEZLA improves skin plaques in moderate
patients, including patients who are biologic-naïve1*

BID, twice daily; BSA, body surface area; ESTEEM, Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis; PASI, Psoriasis Area and Severity Index; sPGA, static Physician Global Assessment.

OTEZLA IMPROVES SCALP PSORIASIS1*

Efficacy in moderate patients is consistent with the overall ESTEEM population

Improvement in scalp psoriasis at week 16 in the ESTEEM moderate patient subset1,a,b

aPooled ESTEEM 1 and ESTEEM 2 studies. Post-hoc analysis of OTEZLA vs placebo at week 16 in moderate patients (baseline sPGA score of 3, BSA of 10% to 15%, PASI score of 12 to 15). A total of 224 patients met these criteria at baseline (OTEZLA, n = 160; placebo, n = 64).

bIncludes all patients in each indicated group with moderate to severe scalp psoriasis (ScPGA ≥3) at baseline; patients with a missing value at week 16 were considered non-responders.

OTEZLA clears or minimizes scalp psoriasis in moderate
patients, including patients who are biologic-naïve1*

ScPGA, Scalp Physician Global Assessment.

OTEZLA IMPROVES NAIL PSORIASIS1*

Efficacy in moderate patients is consistent with the overall ESTEEM population

NAPSI-50 response at week 16, all ESTEEM patients vs moderate patient subset1,a,b

aPooled ESTEEM 1 and ESTEEM 2 studies. Post-hoc analysis of OTEZLA vs placebo at week 16 in moderate patients (baseline sPGA score of 3, BSA of 10% to 15%, PASI score of 12 to 15). A total of 224 patients met these criteria at baseline (OTEZLA, n = 160; placebo, n = 64).

bIncludes all patients in each indicated group with nail psoriasis at baseline (NAPSI score ≥1); patients with a missing value at Week 16 were considered nonresponders.

OTEZLA improves nail psoriasis in moderate
patients, including those who are biologic-naïve1*

NAPSI, Nail Psoriasis Severity Index; PASI, Psoriasis Area and Severity Index.

*OTEZLA is indicated for the treatment of moderate to severe chronic plaque psoriasis in adult patients who failed to respond to, who have a contraindication to, or are intolerant to other systemic therapies. Moderate patients were defined as the subset of moderate to severe patients in the ESTEEM studies with an sPGA score of 3, BSA 10% to 15%, and a PASI score of 12 to 15 at baseline.

Reference:

  1. Iversen L, Paul C, Cirulli J, et al. Efficacy of apremilast versus placebo in patients with lower plaque psoriasis disease activity: results of a pooled, post-hoc analysis of the ESTEEM 1 and 2 trials. Poster presented at: the 26th Congress of the European Academy of Dermatology and Venereology; 13-17 September 2017; Geneva, Switzerland.
You are leaving the OTEZLA® (apremilast) website
Do you wish to leave this site?
OTEZLA International Websites
OTEZLA is approved in 51 Countries
  • United States

  • Canada

  • Australia

  • Israel

  • Switzerland

  • New Zealand

  • Austria

  • Belgium

  • Bulgaria

  • Croatia

  • Republic of Cyprus

  • Czech Republic

  • Denmark

  • Estonia

  • Finland

  • France

  • Germany

  • Greece

  • Hungary

  • Ireland

  • Italy

  • Latvia

  • Lithuania

  • Luxembourg

  • Malta

  • Netherlands

  • Poland

  • Portugal

  • Romania

  • Slovakia

  • Slovenia

  • Spain

  • Sweden

  • United Kingdom

  • Norway

  • Iceland

  • Liechtenstein

  • Russia

  • Japan

  • Hong Kong

  • Singapore

  • Kuwait

  • Taiwan

  • UAE

  • Korea

  • Thailand

  • Lebanon

  • Qatar

  • Argentina

  • Mexico

  • Brazil